23 results on '"Siccardi, Marco"'
Search Results
2. Use of a physiologically based pharmacokinetic model to simulate drug–drug interactions between antineoplastic and antiretroviral drugs
3. Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach
4. Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS
5. A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication
6. Predicting intestinal absorption of raltegravir using a population-based ADME simulation
7. Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells
8. Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg
9. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens
10. Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals
11. Drug interactions: a review of the unseen danger of experimental COVID-19 therapies
12. The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics
13. Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling
14. Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient
15. Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART
16. Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART
17. Use of a physiologically based pharmacokinetic model to simulate drug–drug interactions between antineoplastic and antiretroviral drugs
18. Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach
19. Class-specific relative genetic contribution for key antiretroviral drugs
20. Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots
21. Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS
22. Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling.
23. Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.